Fang Baijun, Song Yongping, Li Ning, Li Jing, Han Qin, Zhao Robert Chunhua
Henan Tumor Hospital, Henan Institute of Haematology, Henan Medical School, Henan University, 127 Dongming Road, Zhengzhou 450008, China.
Ann Hematol. 2009 Mar;88(3):261-6. doi: 10.1007/s00277-008-0599-0. Epub 2008 Sep 4.
Pure red cell aplasia (PRCA) is a well-known, although infrequent, hematological complication after allogeneic hematopoietic stem cell transplantation (HSCT). PRCA occurs in cases of major ABO mismatch between donor and recipient and is believed to be due to inhibition of donor erythroid progenitors by residual host isohemagglutinins. The purpose of our study was to further evaluate the efficacy of human adipose tissue-derived mesenchymal stem cells (AMSC) as the salvage therapy for refractory PRCA after major ABO-incompatible HSCT. Two patients with refractory pure red cell aplasia received intravenous infusions of AMSC at a dose of 1.5 x 10(6)/kg of the patients' weight, and rapid recovery from PRCA without any side effects was observed. We conclude that AMSC seems to be a promising therapeutic option in patients with PRCA after ABO-mismatched HSCT, in whom conventional treatment fails.
纯红细胞再生障碍性贫血（PRCA）是异基因造血干细胞移植（HSCT）后一种虽不常见但广为人知的血液学并发症。PRCA发生于供体与受体之间存在主要ABO血型不匹配的情况下，据信是由于残留的宿主同种血凝素抑制了供体红系祖细胞。我们研究的目的是进一步评估人脂肪组织来源的间充质干细胞（AMSC）作为主要ABO血型不相合HSCT后难治性PRCA挽救治疗的疗效。两名难治性纯红细胞再生障碍性贫血患者接受了静脉输注AMSC，剂量为每千克患者体重1.5×10⁶个细胞，观察到PRCA迅速缓解且无任何副作用。我们得出结论，对于ABO血型不匹配HSCT后常规治疗失败的PRCA患者，AMSC似乎是一种有前景的治疗选择。
